) --




) hit a new 52-week low Tuesday as it is currently trading at $27.55, below its previous 52-week low of $28.04 with five million shares traded as of 3:40 p.m. ET. Average volume has been 2.2 million shares over the past 30 days.

Hospira has a market cap of $4.95 billion and is part of the

health care

sector and


industry. Shares are down 44.4% year to date as of the close of trading on Monday.

Hospira, Inc., a specialty pharmaceutical and medication delivery company, that develops, manufactures, and markets products that help improve the safety and productivity of patient care. The company has a P/E ratio of 19.2, below the average drugs industry P/E ratio of 19.4 and above the S&P 500 P/E ratio of 17.7.

  • Sign up for TheStreet's FREE Dividend and Income Investor Newsletter

TheStreet Ratings rates Hospira as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. You can view the full

Hospira Ratings Report


See all

52-week low stocks

or get investment ideas from our

investment research center